Author + information
- Received August 1, 1988
- Revision received August 11, 1988
- Accepted November 20, 1988
- Published online May 1, 1989.
- Damià Obrador, MD∗,
- Manel Ballester, MD,
- Ignasi Carrio, MD,
- Lluis Berna, MD and
- Guillem Pons-Llado, MD
- ↵∗Address for reprints: Damià Obrador, MD, Departament de Cardiología, Hospital de la Santa Creu i Sant Pau, Avinguda Sant Antoni M. Claret 167, 08025 Barcelona, Spain.
Monoclonal antimyosin antibody studies were Barcelona undertaken to assess the presence of myocardial uptake in patients with chronic idiopathic dilated cardiomyopathy. Three groups were studied: 17 patients with chronic (>12 months) idiopathic dilated cardiomyopathy, 12 patients with a large, poorly contracting left ventricle not due to dilated cardiomyopathy (control patients) and 8 normal individuals. The patients in the cardiomyopathy and control groups showed a similar degree of clinical and functional impairment.
Imaging was undertaken 48 h after antimyosin injection. The heart/lung ratio of antimyosin uptake was used to assess the results. The mean ratio in the cardiomyopathy group was 1.83 ± 0.36 (range 1.40 to 2.80), a value significantly higher than that obtained in the control patients without cardiomyopathy (mean 1.46 ± 0.04, range 1.38 to 1.50) or normal subjects (mean 1.46 ± 0.13, range 1.31 to 1.6) (p < 0.01). No difference in the ratio was noted between the normal subjects and control patients. Abnormal antimyosin uptake was seen in 12 (70%) of the 17 patients with cardiomyopathy and in only 1 (8%) of the 12 control patients. Positive monoclonal antimyosin antibody studies are highly prevalent in chronic idiopathic dilated cardiomyopathy.
☆ This work was supported in part by the Pfeizer Research Award 1986 and by the Fondo de Investigaciones Sanitarias de la Seguridad Social (FISS). Grant No. 950/87.
- Received August 1, 1988.
- Revision received August 11, 1988.
- Accepted November 20, 1988.